bluuebunny/crossref_metadata_2025_split huggingface dataset:
An evaluation of corynebacterium parvum during remission maintenance therapy in pediatric patients with acute lymphoblastic leukemia
Authors: Lankford J. , Nitschke R. , Wells J. , Cox C. , Humphrey G. B. 
Published: February 2007

AbstractThe biologic impact and clinical toxicity of Corynebacterium parvum administered at a dose of 5 mg/M2 by intravenous or subcutaneous routes were evaluated in 18 children receiving combination chemotherapy for maintenance of acute lymphoblastic leukemia (ALL) in remission. Several nonspecific immunologic and hematologic parameters were evaluated. Patients were also monitored for changes in cutaneous sensitivity to histamine. No changes in any parameter were observed in patients after only one course of C parvum injection. However, after 6‐10 courses, glass‐adherent peripheral blood leukocytes of C parvum‐treated patients augmented the response of PHA‐stimulated autologous lymphocytes. In all nine patients studied who received C parvum injection subcutaneously for at least six months, there were significant increases in the mean bone marrow myelocyte‐erythrocyte (ME) volumes compared to pretreatment values. These results suggest that periodic evaluations are desirable in patients receiving repeated administration of C parvum, since changes in immunologic and hematologic responses may be demonstrable only after several injections. In contrast to the reported experience in adults, subcutaneous C parvum administration in children was not well tolerated, whereas intravenous infusion was generally well tolerated.
Ectopic production of human chorionic gonadotropin: A case report
Authors: Erlichman Charles , Pringle J. F. , Quirt I. C. 
Published: February 2007

AbstractThe ectopic production of the β‐subunit of human chorionic gonadotropin (hCG) is described in a patient with an anaplastic carcinoma. After chemotherapy the marker decreased in a logarithmic fashion to undetectable levels but the neoplasm progressed and the patient died. The specificity of the β‐subunit of hCG is discussed. Discordance of the marker and clinical disease is pointed out, and several possible explanations are outlined. The lack of specificity of the β‐subunit of hCG and the discordance that it may exhibit means that its use in diagnosing and following disease progression may be limited.
Immunodiagnosis of childhood all: Problems associated with the use of peripheral blood alone
Authors: Lauer Stephen J. , Casper James T. , Borella Luis D. 
Published: February 2007

AbstractThe immunologic classification of acute lymphoblastic leukemia (ALL) based solely on peripheral blood (PB) cell phenotypes may lead to conflicting results. This was demonstrated by the simultaneous assay of five immunologic markers on PB and bone marrow (BM) cells from 13 children with untreated ALL. We assayed erythrocyte (E) rosettes at 4°C and 37°C, presence of membrane Ig(mIg), and binding of antisera raised against thymus (T), and E− ALL blasts, respectively. At diagnosis, the PB of these children contained > 90% lymphoid cells with 0–48% E rosettes and 1‐84% cells with T antigen(s). Of 7 children with WBC < 10,000/cu mm there were 4 who had 20% or more E rosettes and T‐antigen‐positive cells. Of 6 children with WBC > 10,000/cu mm there were only 2 who had more than 20% E rosettes and T‐antigen‐positive cells. Based on examination of PB alone, six children may have been classified as having T‐like ALL. However, these results were due to the presence of circulating normal T lymphocytes, and assay of BM cells established that only one of the 13 children had T‐like ALL and none had B‐cell ALL. Bone marrow blasts from 12 patients did not form rosettes at 37°C, did not have mIg, and did not react with anti‐T serum. A high proportion of BM blasts from these 12 patients (39‐96%) did react with antiserum against E− ALL blasts. Of these 12 patients 11 had a higher proportion of E− ALL antiserum‐positive blasts in the BM than PB. Thus, immunologic classification of ALL should be based on the study of BM blasts, or both PB and BM cells.
L‐asparaginase used with cytosine arabinoside in treatment of childhood acute lymphocytic leukemia refractory to vincristine and prednisone
Authors: Smithson William A. , Gilchrist Gerald S. , Burgert E. Omer 
Published: February 2007

AbstractEleven patients with acute lymphocytic leukemia in relapse were treated with L‐asparaginase and cytosine arabinoside (1‐β‐D‐arabinofuranosylcytosine) in induction therapy and the same drugs plus cyclophosphamide in maintenance therapy. Three patients had complete remissions lasting 6, 16, and 78+ weeks. One patient experienced partial remission and four had decreased bone marrow or peripheral blasts but were not clinically improved. The responses, which were brief, lasted 1‐16 weeks with one exception of 78+ weeks. Four patients had allergic reactions to L‐asparaginase that were unpredictable with assays of antibodies against L‐asparaginase.
An autopsy study of eye involvement in acute leukemia of childhood
Authors: Robb Richard M. , Ervin Lauri D. , Sallan Stephen E. 
Published: February 2007

AbstractThe eyes of 60 children who had died of acute leukemia between 1968 and 1977 at the Children's Hospital Medical Center have been examined pathologically. An attempt has been made to relate eye findings to the state of the systemic disease at the time of death. Eight of the 60 patients had leukemic retinal infiltrates and all eight had fulminant disease with terminal leukocyte counts over 100,000 per cubic millimeter and a high percentage of „blast”︁ cells. Twenty‐six patients (43%) had leukemic infiltration of the choroid that was inapparent clinically. Choroidal involvement was not correlated with high terminal leukocyte counts but was invariably associated with widespread infiltration of other organs. Four patients had optic nerve involvement; all four had coexistent meningeal leukemia. Isolated retinal hemorrhages could not be correlated with other parameters of the leukemic process.
Cisplatin, bleomycin, and vinblastine combination therapy of testicular tumors: An analysis
Authors: D'aoust Joan C. , Prestayko Archie W. , Einhorn Lawrence H. , Comis Robert L. , Ginsberg Sandra J. , Archambault W. A. T. , Crooke Stanley T. 
Published: February 2007

AbstractA combination regimen consisting of cisplatin, bleomycin, and vinblastine was evaluated in 86 patients with metastatic testicular tumors. Prior therapy included surgical resection of primary tumor (84 patients), radiotherapy (21 patients), chemotherapy (33 patients). Thirteen patients received prior bleomycin and vincristine or vinblastine. Of 80 evaluable patients 51 achieved complete response (CR) and 26 achieved partial response (PR), for an overall response rate 96.5%. There was no significant difference in response rates or survival with respect to prior therapy, sites of metastatic lesions, and tumor histology. The median survival time was not reached in an observation period of 44+ months. Sixty patients were alive 11+–44+ months, and 57 of these were free of disease. Thirty‐two of the 60 patients (53%) had a survival time greater than 20 months. Toxicities included nephrotoxicity (18 patients) leukopenia, (69 patients), thrombocytopenia (nine patients), and anemia (56 patients). Bleomycin‐induced pulmonary toxicity was fatal in one patient. Other toxicities included nausea and vomiting, stomatitis, fever, alopecia, and neurological effects.
Teratomas in children and young adults
Authors: Ganick Dorothy J. , Gilbert Enid F. , Opitz John M. 
Published: February 2007

AbstractA review of all teratomas seen at the University of Wisconsin Hospital between 1965 and 1977 revealed that sacrococcygeal and presacral teratomas were most common. In these cases survival was best in infants less than one year old, with the exception of two cases of malignant medulloepithelioma. Testicular teratomas were predominant in the young adult male, and survival was poor. Pathology and treatment of teratomas are discussed, with an accompanying discussion of congenital anomalies associated with teratomas.
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia
Authors: Wiernik Peter H. , Glidewell Oliver J. , Hoagland H. Clark , Brunner Kurt W. , Spurr Charles L. , Cuttner Janet , Silver Richard T. , Carey Robert W. , Delduca Vincent , Kung Faith H. , Holland James F. 
Published: February 2007

AbstractIn this study 523 previously untreated patients with acute myelocytic leukemia were randomly allocated to induction therapy with daunorubicin 60 mg/M2 daily × 3, cytosine arabinoside and thioguanine 100 mg/M2 each every 12 hours until marrow hypoplasia was achieved, or a 5‐day course of the three drugs with daunorubicin 100 mg/M2 given on dav 1 and cvtosine arabinoside plus thioguanine each given at a dose of 100 mg/M2 every 12 hours for five days. All patients received cyclophosphamide 600 mg/M2 followed in 24 hours by hydroxyurea 500 mg/M2 every six hours for four doses monthly for maintenance therapy. Patients were randomized to receive one of three antimetabolite treatments beginning 24 hours after the last dose of hydroxyurea each month for seven days. One such treatment consisted of 6‐mercaptopurine 100 mg/M2 daily, another group received 6‐thioguanine at the same dose daily, and the third group received 50 mg/M2 of both antimetabolites daily.There were no significant differences in complete response rate, remission duration, or survival among the various treatment groups.
Slipped capital femoral epiphysis following radiotherapy and chemotherapy
Authors: Ryan Beverly R. , Walters Thomas R. 
Published: February 2007

AbstractThere may be an increased frequency of slipped femoral epiphysis in pediatric patients who have received radiation to the pelvic area and combination chemotherapy. Previous reports include bilateral slipping of the epiphysis, eight years after radiation, in a patient with a pelvic neuroblastoma and the occurrence in a patient who had received radiation for Hodgkin disease, with a primary site in the pelvic region. No direct correlation was established in either case.This is a report of two patients who received pelvic radiation and combination chemotherapy who subsequently developed slipped femoral epiphysis. Our purpose is to heighten the suspicion in patients who have received radiation and chemotherapy for pelvic tumors. It is recommended that the femoral heads and acetabula be shielded when their inclusion in the treatment fields is not crucial to the treatment of the underlying disease.
Action of cytosine arabinoside on human tumor cells isolated from malignant effusions: In vitro phosphorylation and inhibition of dna synthesis
Authors: Stahel Rolf A. , Peter Hans‐Jakob , Sauter Christian 
Published: February 2007

AbstractTumor cells were isolated from malignant effusions of three patients with disseminated solid tumors of different origin. Intracellular accumulation of nondiffusible cytosine arabinoside (ara‐C) nucleotides was used to measure phosphorylation. Mouse leukemia L 1210 and L 1210/CA, and ara‐C‐resistant subline, were used as reference cells. Phosphorylation activity was similar in the cells from all three solid tumors and showed a linear increase with drug concentrations of 0.1–100 μg/ml. In contrast to activity in L 1210 cells, the in vitro activity was not saturable at drug levels up to 100 μg/ml. Ara‐C inhibited the incorporation of thymidine into DNA 84%–90% in the solid tumor cells at a concentration of 10 μg/ml. Higher drug concentrations did not result in further inhibition. In one patient, DNA synthesis of tumor cells isolated before and after intraperitoneal instillation of 1,000 mg ara‐C was measured. The in vivo inhibition was found to correspond to the in vitro data.Solid tumor cells isolated from malignant effusion have no greatly reduced capacity for cellular formation of ara‐C/nucleotides, but higher drug levels than achieved with conventional therapy are necessary for sufficient ara‐C nucleotide synthesis.
Ovarian involvement in neuroblastoma
Authors: Meyer William H. , Yu George W. , Milvenan Eileen S. , Jeffs Robert D. , Kaizer Herbert , Leventhal Brigid G. 
Published: February 2007

AbstractA case of neuroblastoma involving the ovaries bilaterally at diagnosis is reported. A review of previous cases of neuroblastoma at Johns Hopkins Hospital revealed no previous occurrence of ovarian metastatic disease at diagnosis, but involvement in about one‐third of cases at autopsy. This appears to be a more common site of metastatic disease than has been previously recognized. The significance of this site of metastases in neuroblastoma is unknown.
Bilateral wilms tumor presenting with acute renal failure and clinical findings mimicking cardiac failure
Authors: Holbrook C. Tate , Crist William M. , Kohaut Edward C. , Buntain William L. 
Published: February 2007

AbstractA six‐year‐old girl presented with clinical signs and symptoms of right‐sided heart failure. Cardiac catheterization demonstrated filling defects in both pulmonary arteries felt to represent metastatic lesions or thromboemboli. Intravenous pyelogram revealed bilateral renal masses and intrarenal obstruction. Acute renal failure was unresponsive to standard therapy. An open renal biopsy revealed Wilms tumor with favorable histology. Aggressive chemotherapy and irradiation were undertaken and renal function returned. This case adds to the heterogeneity of presentations described for Wilms tumor, and review of the literature reveals no other cases with similar presenting signs.
Improved remission induction rate with D‐ZAPO but unimproved remission duration with addition of immunotherapy to chemotherapy in previously untreated children with ANLL
Authors: Baehner Robert L. , Bernstein Irwin D. , Sather Harland , Higgins Gussie , McCreadie Samuel , Chard Ronald L. , Hammond Denman ,   Children's Cancer Study Group
Published: February 2007

AbstractIn 163 children with acute nonlymphocytic leukemia (ANLL), a D‐ZAPO induction program consisting of daunomycin, 5‐azacytidine, cytosine arabinoside, prednisone, and vincristine resulted in a remission rate of 71.8%. Immunologic therapy was employed during maintenance with the aim of prolonging remission and improving survival. The administration of immunotherapy consisting of a mixture of bacillus Calmette‐Guérin (BCG) and allogeneic acute myelomonocytic leukemic cells injected intradermally on day 14 of each of the first three monthly cycles of 6‐thioguanine for ten days, 5‐azacytidine and cytosine arabinoside for four days, and vincristine for one day did not improve remission duration or survival compared to that due to chemotherapy alone. Important prognostic factors identified in this study included a remission induction rate significantly better for females than males (P = 0.04), for children between the ages of 5 and 10 years compared to those greater than this age group (P = 0.01), and a prolonged remission duration (P = 0.04), and survival (P < 0.01) for patients with initial white blood counts of <20 × 109/liter.
Histiocytosis X: Clinical trial of chlorambucil: A report from childrens cancer study group
Authors: Lahey M. E. , Heyn R. M. , Newton W. A. , Shore N. , Smith W. B. , Leikin S. , Hammond D. 
Published: February 2007

AbstractA prospective study for histiocytosis X was designed to determine whether “good risk” patients, ie, those without evidence of dysfunction of liver, lung, or hemopoietic system, would respond to single agent therapy; in this case chlorambucil (CMB) used in a dose of 5 mgm/m2 /day. If there was no response after an adequate trial period, treatment was initiated with four drugs using a combination of prednisone, vinblastine, cyclophosphamide and methotrexate. There were 26 evaluable patients, 57% of whom were less than two years of age at onset of therapy. There were three complete and four partial responses to CMB for a response rate of 26.9%. Sixteen patients received an adequate trial of four‐drug therapy with three complete and two partial responses for a response rate of 33%. These responses were inferior to those previously reported for either single agents or combined therapy in histiocytosis X.
Antiemetic effect of intravenous diazepam in patients receiving cis‐diamminedichloroplatinum II: A pilot study
Authors: Robins H. Ian , Ershler William B. , de Jongh Leon , Chang Yuang‐Chi , Drozdowicz Paulette M. , Carr Brian I. , Meyer Deborah K. 
Published: February 2007

AbstractA pilot study suggesting the usefulness of intravenous diazepam as an antiemetic for adult patients receiving cis‐diamminedichloroplatinum is presented. Observations included 24 patients and 34 courses of therapy. Patients received diazepam and prochlorperazine, and the incidence of vomiting and subjective evaluation of nausea were compared to previous courses of therapy with prochlorperazine alone. A positive response was observed in 87% of the patients. Use of other antiemetics is briefly reviewed.
L‐asparaginase effect on antithrombin‐III levels
Authors: Anderson Norwood , Lokich Jacob J. , Tullis James L. 
Published: February 2007

AbstractThe effect of L‐asparaginase (L‐asp) therapy on circulating antithrombin‐III (AT‐III) was monitored in three patients with acute lymphoblastic leukemia. Serial determination for AT‐III by both a functional assay and an immunologic assay demonstrated a rapid decrease in serum AT‐III levels, followed by a protracted recovery beyond the period of L‐asp exposure. One of the three patients developed a reversible venous thrombosis of the arm. The mechanism of the L‐asparaginase effect may be related to peripheral degradation of AT‐III or to inhibition of production.
Ewing sarcoma: Phalangeal primary with fatal cardiac metastases
Authors: Wilson Kenneth S. , Nyssen John , Alexander Skaria 
Published: February 2007

AbstractA 39‐year‐old man had pain and swelling of the terminal phalanx of a finger. Radiograph was interpreted as osteomyelitis, and amputation through the midphalanx was performed. Histology revealed Ewing sarcoma. Lung metastases rapidly developed. Right lung irradiation and systemic chemotherapy, including doxorubicin, were instituted. He developed progressive severe right ventricular failure which was attributed to effects of large pulmonary metastases. Autopsy showed massive right ventricular metastases, the primary pathological cause of the heart failure, without evidence of doxorubicin cardiomyopathy.
A new therapy schedule for pediatric non‐Hodgkin lymphoma toxicity and preliminary results
Authors: Meadows A. T. , Jenkin R. D. T. , Anderson J. , Chilcote R. , Coccia P. , Exelby P. , Kushner J. , Leikin S. , Siegel S. , Wilson J. F. , Hammond D. 
Published: February 2007

AbstractA pilot study of the toxicity and efficacy of a new treatment schedule for childhood non‐Hodgkin's lymphoma was conducted by members of the Children's Cancer Study Group (CCSG) prior to its use in a randomized phase III trial. Chemotherapeutic agents used were cyclophosphamide (CPM), vincristine (VCR), and prednisone, together with intravenous (IV) and intrathecal methotrexate (IT MTX). Radiation therapy was also employed.From September 1976 to April 1977, 27 eligible, newly diagnosed patients with non‐Hodgkin's lymphoma were entered onto this pilot study. Toxicity was acceptable with minor adjustments in dosage and timing of the myelosuppressive agents. Fourteen of the 22 patients entered onto maintenance remain entirely disease‐free, and all have completed the prescribed course of chemotherapy. None of the 12 patients characterized as having a “favorable” prognosis has relapsed, with a median follow‐up of 27 months from on study.
Prophylactic Co‐trimoxazole and lactobacilli preparation in neutropenic patients
Authors: Ekert H. , Jurk I. H. , Waters K. D. , Tiedemann K. 
Published: February 2007

AbstractA randomized study of intestinal decontamination was undertaken in 68 children with leukemia and solid tumours. Framycetin, colymycin, nystatin, and metronidazole were given in 35 neutropenic episodes in 33 children, while co‐trimoxazole and lactobacilli preparation were administered in 35 episodes in 35 children. The diseases, severity of neutropenia, and incidence of infection at entry into study were comparable in the two groups. There was no significant difference in the incidence of infections developing during the phase of neutropenia. The median and range of time required to recover from neutropenia were also not different. Co‐trimoxazole and lactobacilli were significantly better tolerated, there being no nausea and vomiting, no refusal to take medication, no dose reduction or change to an alternative regimen. We conclude that co‐trimoxazole and lactobacilli preparation improve quality of life during a neutropenic episode and have the additional advantage of being relatively inexpensive.
Retinoids for the prevention of epithelial cancers: Current status and future potential
Authors: Clamon Gerald H. 
Published: February 2007

AbstractPrevention of epithelial cancers is needed, as the treatment of such cancers in the advanced state has failed. Vitamin A and its structural analogs called retinoids will prevent cancers of the lung, breast, bladder, stomach, and cervix in animals exposed to carcinogens. Synthetic retinoids offer less toxicity than natural retinoids and may be acceptable to human trials. Identification of a suitable group at risk for an epithelial cancer which might be reasonably expected to benefit from retinoids should precede planning of a clinical trial.
Long‐term survivors of high‐grade malignant astrocytomas
Authors: Dara P. , Slater L. M. , Talreja D. , Armentrout S. A. 
Published: February 2007

AbstractThis report describes our experience with 40 evaluable patients with high‐grade malignant astrocytomas. Eleven patients were treated with surgery and radiotherapy; 29 patients were treatedwith surgery, radiotherapy, and BCNU chemotherapy. Ten of these 29 patients are two‐year survivors. Their mean survival is over 57.3 months, and they have been off chemotherapy for one to 27 months, mean 13.7 months. Seven of these patients received 800 to 1,100 mg/m2 of BCNU; three other long survivors received greater amounts of BCNU. Our current recommendation is that patients with high‐grade malignant astrocytomas be treated with surgery, radiotherapy, and at least 800 mg/m2 of BCNU.
Cis‐platinum therapy of previously treated head and neck cancer: The Southwest Oncology Group's two‐dose‐per‐month outpatient regimen
Authors: Panettiere Frank J. , Lehane Daniel , Fletcher William S. , Stephens Ronald , McCracken J. Dean , Rivkin Saul 
Published: February 2007

AbstractThe Southwest Oncology Group tested an outpatient Cis‐platinum regimen in patients with carcinoma of the head and neck. Courses which consisted to two doses, a week apart, were scheduled to be given at 4‐week intervals. Eighty‐nine poor risk head and neck cancer patients, who had received extensive prior therapy with surgery, radiation, and/or multiple drugs were studied. Sixteen (18% of all entered and 25% of the 65 fully evaluable) had objective tumor regression. The median duration of response was 136 days. Toxicity was moderate. Myelosuppression was minimal with only 3% of patients exhibiting leukocyte nadirs below 2,000 and less than 2% experiencing platelet counts below 50,000. Significant, but reversible, impairment of renal function occurred in 8% of patients. Individual susceptibility to such renal toxicity appears to have been predictable. This simple outpatient program with its effectiveness and minimal toxicity in poor risk patients deserves further utilization.